Ibrutinib, the initial BTK inhibitor approved by the U.S. Food and Drug Administration (FDA), has demonstrated exceptional effectiveness in addressing B-cell malignancies like CLL and MCL [7]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.